Real-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product
Claude Bergeron, M.Sc., A.S.A.
Advertisement
Senior Director, Pharmaceutical & Biotech Solutions, McKesson Specialty Health
Articles by Claude Bergeron, M.Sc., A.S.A.
Advertisement
Latest Updated Articles
- Outcomes Data: A Critical Insight for Market Access
Published: October 9th 2013 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
5
